FibroScan评价ALT升高慢性乙型肝炎患者抗病毒疗效价值

摘要/Abstract

摘要： 目的研究瞬时弹性诊断仪(FibroScan)在血清丙氨酸氨基转移酶(ALT)轻度升高的慢性乙型肝炎患者抗病毒疗效评估中的价值。方法 2016年5月至2019年5月收治的ALT轻度升高慢性乙型肝炎患者80例, 按照治疗方式的不同分为观察组(52例, 核苷类抗病毒药物治疗)和对照组(28例, 复方甘草酸苷＋五酯胶囊＋双环醇治疗)。比较两组治疗前及治疗12个月后ALT、天冬氨酸氨基转移酶(AST)、乙型肝炎病毒基因(HBV DNA)、FibroScan值。结果治疗12个月后, 两组ALT、AST均显著低于治疗前(P<0.05), 且观察组上述指标均显著低于对照组(P<0.05)。治疗12个月后, 观察组HBV DNA、FibroScan值均显著低于治疗前(P<0.05), 且上述指标均显著低于对照组(P<0.05)。结论 FibroScan对ALT轻度升高的慢性乙型肝炎患者抗病毒治疗具有良好的指导作用, 值得临床积极推广。

关键词: 瞬时弹性诊断仪, 丙氨酸氨基转移酶, 慢性乙型肝炎, 抗病毒

Abstract: Objective To study on the value of FibroScan in evaluating the efficacy of antiviral therapy for patients with chronic hepatitis B (CHB) and slightly elevated serum level of alanine aminotransferase (ALT).Methods Eighty cases of chronic hepatitis B patients with mildly elevated ALT were divided into an observation group and a control group according to different treatments that they had received. Patients in the observation group were treated with nucleoside antiviral drug (N=52), while patients in the control group were treated with glycyrrhizin in combination with five ester capsule and bicyclol) (N=28). Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), hepatitis B viral load (HBV DNA) and Fibroscan values were compared between these two groups of patients at before and 12 months after the treatments. Results After 12 months of treatments, ALT and AST levels in both groups of patients were significantly lower than those before treatments (P<0.05), and the above indexes in the observation group were significantly lower than those in the control group (P<0.05). The HBV DNA load and FibroScan values in the observation group were significantly lower than those before treatment (P<0.05), and both indexes were significantly lower than those in the control group (P<0.05).Conclusion FibroScan has a good evaluating performance for antiviral treatment in patients with chronic hepatitis B and mildly elevated ALT, which is worthy of active promotion in clinical practice.

Key words: FibroScan, Alanine aminotransferase, Chronic hepatitis B, Antiviral therapy

田颖颖, 丁洁, 徐毅明. FibroScan评价ALT升高慢性乙型肝炎患者抗病毒疗效价值[J]. 肝脏, 2021, 26(4): 381-383.

TIAN Ying-ying, DING Jie, XU Yi-ming. Evaluation of the efficacy of antiviral therapy with FibroScan for chronic hepatitis B patients with mildly elevated ALT[J]. Chinese Hepatolgy, 2021, 26(4): 381-383.

参考文献

[1] 张露, 范志芳, 刘殿武, 等. 1990—2016年中国乙型肝炎引起的肝硬化及其他慢性肝病疾病负担变化趋势分析. 中华流行病学杂志, 2020, 41:173-177.
[2] 代佩, 王晓南, 官旭华, 等. 2012—2017年湖北省急性乙型病毒性肝炎流行病学分析. 现代预防医学, 2019, 46:5-8.
[3] 贾继东, 侯金林, 魏来, 等. 《慢性乙型肝炎防治指南(2019年版)》新亮点. 中华肝脏病杂志, 2020, 28:21-23.
[4] 杨小军, 张国梁, 刘永华, 等. 218例超声引导下经皮肝穿刺活检术与慢性肝病临床诊断的相关性分析. 安徽医药, 2018, 22:2172-2175.
[5] 周晓颖, 王琳, 崔祖丽. Fibroscan对乙型肝炎并发酒精性肝病患者肝脏纤维化的诊断效果. 肝脏, 2019, 24:1058-1060.
[6] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版). 中华实验和临床感染病杂志(电子版), 2015, 9:570-589.
[7] 梁丽, 李红艺, 任江波, 等. 长期恩替卡韦抗病毒治疗对老年慢性乙型肝炎患者肾脏功能的影响. 中华老年医学杂志, 2019, 38:1258-1261.
[8] 胡乾坤, 黄玉仙. 预测慢性乙型肝炎抗病毒疗效和停药复发的新型血清标志物的研究进展. 中华传染病杂志, 2019, 37:764-768.
[9] Chon YE, Park JY, Myoung SM, et al. Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis. Am J Gastroenterol, 2017, 112:882-891.
[10] 陈晨, 翟玉峰, 张怀宏. APRI对ALT<2倍正常值上限慢性HBV感染抗病毒治疗指征的判断价值. 临床肝胆病杂志, 2018, 34:1005-1010.
[11] 丁洋, 窦晓光. ALT正常的慢性乙型肝炎抗病毒治疗策略. 临床肝胆病杂志, 2018, 34:926-929.
[12] Afdhal NH, Bacon BR, Patel K, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a united states multicenter study. Clin Gastroenterol Hepatol, 2015, 13:772-779.
[13] 丁荣蓉, 陆伟, 王雁冰, 等. 采用瞬时弹性成像技术和血清标志物预测丙氨酸转氨酶轻度升高的慢性乙型肝炎患者肝纤维化程度. 中华传染病杂志, 2019, 37:72-76.
[14] 杨东亮. 丙氨酸转氨酶复常在乙型肝炎抗病毒治疗中的价值 . 中华肝脏病杂志, 2019, 27:741-747.
[15] 周保仓. 转氨酶正常或轻度增高的慢性乙型肝炎患者肝穿刺活检病理特征. 肝脏, 2019, 24:253-256.
[16] 穆晓洁, 孟繁坤. 血清ALT、AST、TBiL与慢性乙型肝炎患者FibroScan弹性值的相关性. 医学影像学杂志, 2016, 26:1642-1644.
[17] 段维佳, 王晓明, 王宇, 等. FibroTouch和FibroScan检测评估慢性乙型肝炎患者肝纤维化程度的诊断价值. 中华实验和临床病毒学杂志, 2018, 32:399-402.